Volume 4 Supplement 2
Relation between autophagy and the resistence of glioblastoma cells to temozolomide
© Carmo et al; licensee BioMed Central Ltd. 2010
Published: 24 September 2010
Gliomas are brain tumours that account for more than 50% of the tumours that arise within the central nervous system. They are highly proliferative, angiogenic, and develop resistance to the alkylating agents used in chemotherapy. The median survival time for glioma patients remains approximately 12-14 months in patients treated with temozolomide (TMZ) which is considered the main chemotherapeutic agent. In order to understand the cellular mechanisms involved in chemoresistance of glioma cells we analysed the activation of autophagy in cells treated with TMZ. In addition, we determined the effect of TMZ in the survival pathways PI3K/Akt and MAP kinases. For that, U-118 glioma cells were incubated with different concentrations of TMZ for different periods of time. Activation of autophagy and of PI3K/Akt and MAP kinase was evaluated by western blot. Apoptosis was addressed by confocal microscopy and by flow cytometry. The results indicated that in glioma cells treated with TMZ there was an increased expression of LC3 indicated that TMZ activated autophagy. Glioma cells presented a basal activation of PI3K/Akt and MAP kinases which was not blocked by TMZ. TMZ was also unable to induce apoptosis in a significant percentage of cells. Together, these results suggested that chemoresistance of glioma cells to TMZ is due to TMZ inability to block the activation of the survival pathways of autophagy, PI3K/Akt and MAP kinases.
- Ziegler DS, Kung AL, Kieran MW: Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol. 2008, 20: 493-500. 10.1200/JCO.2007.13.9717.View ArticleGoogle Scholar
- Thorburn A: Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis. 2008, 13: 1-9. 10.1007/s10495-007-0154-9.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.